Lilly expects the FDA decision on Omvoh/mirikizumab in the United States later in 2023. Omvoh has been launched in Japan and the EU. Regulatory action for lebrikizumab is expected in the EU later this year. Earlier this month, the FDA issued a complete response letter to its biologic license application seeking approval of lebrikizumab for moderate-to-severe atopic dermatitis. The FDA's decision on Jaypirca for the chronic lymphocytic leukemia indication and donanemab for early Alzheimer's disease is expected by the end of 2023.